Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients
Background: Metabolic syndrome (MetS) and nonalcoholic fatty liver disease have become a common finding in HIV-infected patients. However, the severity, risk factors and pathogenesis of liver fibrosis in this population have been poorly documented. Objectives: To assess the impact of MetS on liver fibrosis and analyze the association between MetS, liver fibrosis and markers of adipose tissue and macrophage activation. Methods: In a matched cohort of HIV-1-monoinfected patients with and without MetS, after exclusion of other causes of liver disease, we assessed liver stiffness measurement and measured levels of serum adipokines, homeostasis model assessment index and soluble CD163 (sCD163) and CD14 as markers of fat, insulin resistance and macrophage/monocyte activation, respectively. Results: A total of 468 HIV-monoinfected individuals were enrolled; 405 (203 with MetS/202 without MetS) were analyzed. Patients with MetS were older and 49% had insulin resistance. The prevalence of significant liver fibrosis (≥F2) was higher in patients with MetS [25.1%, 95% confidence interval (19.3–31.2)] compared with those without MetS [7.9%, (4.6–12.5), P
Publication date: Available online 20 October 2019Source: American Heart JournalAuthor(s): Neha J. Pagidipati, Yinggan Zheng, Jennifer B. Green, Darren K. McGuire, Robert J. Mentz, Svati Shah, Pablo Aschner, Tuncay Delibasi, Helena W. Rodbard, Cynthia M. Westerhout, Rury R. Holman, Eric D. Peterson, on behalf of the TECOS Study GroupAbstractBackgroundObesity is a risk factor for type 2 diabetes (T2D) and cardiovascular disease (CVD). Whether obesity affects outcomes among those with T2D and atherosclerotic CVD (ASCVD) remains uncertain. Our objective was to investigate the relationship between body mass index (BMI) and ASC...
Conditions: Type 1 Diabetes; Insulin Sensitivity/Resistance Interventions: Drug: GLP-1; Drug: Insulin; Drug: Dextrose 20 % in Water Sponsors: University of Virginia; American Diabetes Association; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Recruiting
Condition: Obesity Intervention: Diagnostic Test: IL-6, Clusterin, Irisin Level Sponsors: Rehab Werida; Tanta University Completed
Condition: Obesity Intervention: Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis Completed
Conditions: Dyslipidemias; Metabolic Syndrome; Sedentary Behavior; Obesity; Blood Pressure Interventions: Behavioral: Low Volume-High Intensity Interval Training; Behavioral: Moderate Intensity Continuous Training Sponsors: Coventry University; INGESPORT HEALTH AND SPA CONSULTING SL Not yet recruiting
Condition: HIV-1 Infection Intervention: Other: Samplings Sponsors: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); ViiV Healthcare Not yet recruiting
Condition: Child Obesity Intervention: Behavioral: Sports Readiness Intervention Sponsors: University of Alabama at Birmingham; The Birmingham City School System Not yet recruiting
This study was carried out in strict accordance with recommendations of the National Institutes of Health guide for the care and use of Laboratory animals. Before undergoing the experimental work, the protocol was approved by the Comité Institutionnel de Protection des Animaux (CIPA) of UQAM (Permit Number: 0515-R3–759-0516). After a 3-day acclimatization period at UQAM’s animal facility, young (100–125 g; approximately 4 weeks old) male Wistar rats (Charles River, St-Constant, QC, Canada) were randomly fed with a regular chow diet (RCD; n = 13) or HFD (n = 12) for 14&...
Authors: Perazzo H, Cardoso SW, Yanavich C, Nunes EP, Morata M, Gorni N, da Silva PS, Cardoso C, Almeida C, Luz P, Veloso VG, Grinsztejn B Abstract INTRODUCTION: Non-alcoholic fatty liver disease is characterized by the presence of hepatic steatosis and can be associated with fibrosis progression, development of cirrhosis and liver-related complications. Data on the prevalence of liver fibrosis and steatosis in HIV patients remain contradictory in resource-limited settings. We aimed to describe the prevalence and factors associated with liver fibrosis and steatosis in patients with HIV mono-infection under long-ter...